Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

Recruiting

Phase 1

OmadacyclineStudy to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections

Sponsor:

Paratek Pharmaceuticals Inc

Code:

NCT05217537

Conditions

Bacterial Infections

Eligibility Criteria

Sex: All

Age: 8 - 17

Healthy Volunteers: Not accepted

Interventions

Omadacycline Injection [Nuzyra]

Omadacycline Oral Tablet

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Paratek Pharmaceuticals Inc on 2024-08-22.